Biotech startups that raised Series D or later in Asia
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Drug Farm | Shanghai | Series D | $55.0M | 2026-07-13 |
| Vivolight | Nanshanqu | Series E | $13.9M | 2026-06-01 |
| Full-Life Technologies | Shanghai | Series D | $109.0M | 2026-05-18 |
| New Radiomedicine Technology | Chengdu | Series E | $145.4M | 2026-04-03 |
| CORXEL Pharmaceuticals | Shanghai | Series D | $287.0M | 2026-01-22 |
| MAXVAX | Shuangliu | Series D | $27.4M | 2025-12-25 |
| METiS Pharmaceuticals | Hangzhou | Series D | $55.7M | 2025-08-04 |
| IMPACT Therapeutics | Nanjing | Series D | $34.6M | 2024-11-15 |
8 rows of the CSV in 5 of its 18 columns.
- The 98 biotech startups in Asia whose last round is Series D or later have raised $8.0B in total.
- 19 of them closed their most recent round in the last 12 months, $1.2B combined.
- The largest of those rounds is CORXEL Pharmaceuticals' $287.0M Series D, dated January 2026.
- The most recent is GeneMind Biosciences' $89.5M Series D on 10 September 2026.
- IDG Capital is an investor in 2 of them, more than any other fund.
- Health care is the most common other sector, with 86 companies (88%).
- 3% were founded in 2020 or later; the median founding year is 2013.
- The most common team size is 11 to 50 employees (29% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
13 of 98| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Drug Farm | Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. | Artificial intelligence | Shanghai, China | Series D | $55.0M | 2026-07-13 | $138.0M | DT Capital Partners, South China Venture Capital, BVCF +1 | 101 to 250 | 2015 |
| Vivolight | Vivolight conducts medical research and develops intravascular interventional imaging technology. | Biotech | Nanshanqu, China | Series E | $13.9M | 2026-06-01 | $52.2M | CAS Star, TusStar | 51 to 100 | 2012 |
| Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Shanghai, China | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| New Radiomedicine Technology | New Radiomedicine Technology supplies medical isotopes in China. | Biotech | Chengdu, China | Series E | $145.4M | 2026-04-03 | $330.6M | Chengdu Science and Technology Venture Capital | 101 to 250 | 2016 |
| CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Shanghai, China | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| MAXVAX | MAXVAX develops and commercializes novel vaccines. | Biotech | Shuangliu, China | Series D | $27.4M | 2025-12-25 | $284.2M | IDG Capital, Shenzhen Capital Group, Korea Investment Partners +1 | 251 to 500 | 2016 |
| METiS Pharmaceuticals | METiS Pharmaceuticals is an AI-driven drug formulation company. | Artificial intelligence | Hangzhou, China | Series D | $55.7M | 2025-08-04 | $391.7M | Source Code Capital, Frees Fund, Luminous Ventures (former Lightspeed China Partners) | 51 to 100 | 2020 |
| IMPACT Therapeutics | IMPACT Therapeutics develops similar drugs to treat cancer. | Biotech | Nanjing, China | Series D | $34.6M | 2024-11-15 | BioVenture, Lilly Asia Ventures, Decheng Capital +2 | 51 to 100 | 2009 | |
| Yidao Biotechnology | Yidao Biotechnology researches and develops vaccines and biomedical products. | Biotech | Suzhou, China | Series D | $25.2M | 2024-05-09 | Qiming Venture Partners, Northern Light Venture Capital | 2017 | ||
| Atom Bioscience & Pharmaceutical | Atom Bioscience is a clinical-stage biotechnology company. | Biotech | Suzhou, China | Series D | $82.1M | 2023-10-16 | Fortune Venture Capital, Oriza Holdings, Kaitai Capital +1 | 11 to 50 | 2012 | |
| Accellix | Accellix provides an assay delivery platform. | Biotech | Jerusalem, Israel | Series E | $10.0M | 2021-12-13 | BroadOak Capital Partners | 51 to 100 | 2013 | |
| DXY Unicorn | DXY is an online healthcare community connecting doctors, consumers, and healthcare organizations. | Biotech | Hangzhou, China | Series E | $500.0M | 2020-12-29 | $682.0M | Shunwei Capital, DCM Ventures, Legend Capital +1 | 101 to 250 | 2000 |
| Nutrinia | Nutrinia develops therapies for patients with intestinal failure. | Biotech | Ramat Gan, Israel | Series D | $30.0M | 2016-08-18 | OrbiMed, Pontifax, WuXi Healthcare Ventures +2 | 11 to 50 | 2003 |
Table 1. Biotech startups that raised Series D or later in Asia: the 13 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 98.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Shanghai, China | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| 2 | New Radiomedicine Technology | New Radiomedicine Technology supplies medical isotopes in China. | Biotech | Chengdu, China | Series E | $145.4M | 2026-04-03 | $330.6M | Chengdu Science and Technology Venture Capital | 101 to 250 | 2016 |
| 3 | Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Shanghai, China | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| 4 | Drug Farm | Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. | Artificial intelligence | Shanghai, China | Series D | $55.0M | 2026-07-13 | $138.0M | DT Capital Partners, South China Venture Capital, BVCF +1 | 101 to 250 | 2015 |
| 5 | MAXVAX | MAXVAX develops and commercializes novel vaccines. | Biotech | Shuangliu, China | Series D | $27.4M | 2025-12-25 | $284.2M | IDG Capital, Shenzhen Capital Group, Korea Investment Partners +1 | 251 to 500 | 2016 |
| 6 | Vivolight | Vivolight conducts medical research and develops intravascular interventional imaging technology. | Biotech | Nanshanqu, China | Series E | $13.9M | 2026-06-01 | $52.2M | CAS Star, TusStar | 51 to 100 | 2012 |
Table 2. Biotech startups that raised Series D or later in Asia: the 6 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | IDG Capital | Private equity firm | Beijing, China | 2 | 2% | 1 | MAXVAX |
| 2 | WuXi Healthcare Ventures | Venture capital firm | Cambridge, United States | 2 | 2% | ||
| 3 | EFung Capital | Private equity firm | Shenzhen, China | 2 | 2% | ||
| 4 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 2% | ||
| 5 | South China Venture Capital | Private equity firm | Shenzhen, China | 1 | 1% | 1 | Drug Farm |
| 6 | YD Capital | Private equity firm | Prague, Czech Republic | 1 | 1% | 1 | Drug Farm |
| 7 | BVCF | Private equity firm | Shanghai, China | 1 | 1% | 1 | Drug Farm |
| 8 | DT Capital Partners | Private equity firm | Shanghai, China | 1 | 1% | 1 | Drug Farm |
| 9 | CAS Star | Startup incubator | Xian, China | 1 | 1% | 1 | Vivolight |
| 10 | TusStar | Startup accelerator | Beijing, China | 1 | 1% | 1 | Vivolight |
| 11 | Summer Capital | Private equity firm | Hong Kong | 1 | 1% | 1 | Full-Life Technologies |
| 12 | Sky9 Capital | Venture capital firm | 1 | 1% | 1 | Full-Life Technologies | |
| 13 | Chengwei Capital | Venture capital firm | Shanghai, China | 1 | 1% | 1 | Full-Life Technologies |
| 14 | Prosperity7 Ventures | Venture capital firm | Dhahran, Saudi Arabia | 1 | 1% | 1 | Full-Life Technologies |
| 15 | Chengdu Science and Technology Venture Capital | Venture capital firm | Chengdu, China | 1 | 1% | 1 | New Radiomedicine Technology |
Table 3. Biotech startups that raised Series D or later in Asia: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 86 | 88% | $7.2B |
| Software | 8 | 8% | $1.2B |
| Artificial intelligence | 4 | 4% | $529.7M |
| Hardware | 3 | 3% | |
| Cybersecurity | 1 | 1% |
Table 4. Biotech startups that raised Series D or later in Asia by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series D+ | 98 | 100% | $36.9M |
Table 5. Biotech startups that raised Series D or later in Asia by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| China | 74 | 76% |
| Israel | 11 | 11% |
| Japan | 4 | 4% |
| India | 3 | 3% |
| South Korea | 3 | 3% |
| Taiwan | 2 | 2% |
| Singapore | 1 | 1% |
Table 6. Biotech startups that raised Series D or later in Asia by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Shanghai | 20 | 20% |
| Beijing | 11 | 11% |
| Hangzhou | 7 | 7% |
| Suzhou | 6 | 6% |
| Tokyo | 3 | 3% |
| Nanjing | 3 | 3% |
| Shenzhen | 2 | 2% |
| Wuhan | 2 | 2% |
| Changzhou | 2 | 2% |
| Guangzhou | 2 | 2% |
| Minhang | 2 | 2% |
| Caesarea | 2 | 2% |
Table 7. Biotech startups that raised Series D or later in Asia by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| September 2026 | 3 | 16% | $208.7M |
| August 2026 | 1 | 5% | $97.1M |
| July 2026 | 2 | 11% | $91.9M |
| June 2026 | 2 | 11% | $60.8M |
| May 2026 | 2 | 11% | $116.9M |
| April 2026 | 1 | 5% | $145.4M |
| March 2026 | 2 | 11% | $46.0M |
| January 2026 | 2 | 11% | $294.7M |
| December 2025 | 4 | 21% | $137.5M |
Table 8. Biotech startups that raised Series D or later in Asia: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 15 | 15% | $1.1B |
| 2025 | 12 | 12% | $350.9M |
| 2024 | 8 | 8% | $212.7M |
| 2023 | 10 | 10% | $316.3M |
| 2022 | 9 | 9% | $261.4M |
| 2021 | 14 | 14% | $909.5M |
Table 9. Biotech startups that raised Series D or later in Asia by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 3 | 3% |
| 2015 to 2019 | 31 | 32% |
| 2010 to 2014 | 34 | 35% |
| Before 2010 | 30 | 31% |
Table 10. Biotech startups that raised Series D or later in Asia by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 5 | 5% |
| 11 to 50 | 28 | 29% |
| 51 to 100 | 17 | 18% |
| 101 to 250 | 24 | 25% |
| 251 to 500 | 8 | 8% |
| 501 to 1,000 | 11 | 11% |
| 1,001 to 5,000 | 2 | 2% |
| 5,001 to 10,000 | 1 | 1% |
Table 11. Biotech startups that raised Series D or later in Asia by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series D or later and its headquarters is in Asia. On 16 November 2026 that is 98 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 13 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 98 rows: 20 have no round amount, 0 no city and 24 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Asia whose last round is Series D or later are on the list?
- 98, in the file dated 16 November 2026. 19 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 98 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.